On June 7th, CoLucid Pharmaceuticals (NasdaqCM: CLCD) announced the completion of
enrollment in the SAMURAI Phase III study, the first of two pivotal studies evaluating oral
lasmiditan as an acute treatment for migraines. CoLucid is developing oral lasmiditan as a firstline
therapy for migraine sufferers who are contraindicated from using triptans, the current
standard-of-care, due to cardiovascular conditions or risk factors. The Company plans to
include data from the ongoing SAMURAI and SPARTAN Phase III studies in a potential
NDA submission for oral lasmiditan. CoLucid expects to report topline SAMURAI data in
the third quarter of 2016, and results from the SPARTAN trial are expected in the middle
of 2017.
For full access, please click here.
For full access, please click here.
